MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- AJANTA PHARMA LTD. (pharmaceuticals)
- Latest 8 Quarter Result
AJANTA PHARMA Quarterly Results (AJPH)
Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
AJANTA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 5,871 | 5,303 | 5,110 | 5,441 | 4,851 | 5,152 | 6,119 | 6,428 | |
| Other income | Rs m | 152 | 52 | 81 | 152 | 44 | 16 | 76 | 132 | |
| Turnover | Rs m | 6,022 | 5,356 | 5,191 | 5,594 | 4,895 | 5,168 | 6,196 | 6,560 | |
| Expenses | Rs m | 3,896 | 3,908 | 3,535 | 3,779 | 3,778 | 3,881 | 4,436 | 4,651 | |
| Gross profit | Rs m | 1,975 | 1,395 | 1,575 | 1,662 | 1,073 | 1,271 | 1,684 | 1,766 | |
| Depreciation | Rs m | 150 | 166 | 172 | 175 | 187 | 188 | 228 | 233 | |
| Interest | Rs m | 1 | 1 | 2 | 1 | 1 | 8 | 18 | 49 | |
| Profit before tax | Rs m | 1,975 | 1,280 | 1,483 | 1,638 | 930 | 1,092 | 1,515 | 1,616 | |
| Tax | Rs m | 501 | 335 | 425 | 385 | 261 | 203 | 368 | 452 | |
| Profit after tax | Rs m | 1,475 | 945 | 1,058 | 1,254 | 669 | 889 | 1,146 | 1,164 | |
| Gross profit margin | % | 33.6 | 26.3 | 30.8 | 30.5 | 22.1 | 24.7 | 27.5 | 27.5 | |
| Effective tax rate | % | 25.3 | 26.2 | 28.7 | 23.5 | 28.0 | 18.6 | 24.3 | 28.0 | |
| Net profit margin | % | 25.1 | 17.8 | 20.7 | 23.0 | 13.8 | 17.3 | 18.7 | 18.1 | |
| Diluted EPS | Rs | 16.8 | 10.7 | 12.0 | 14.3 | 7.6 | 10.1 | 13.0 | 13.2 | |
| Diluted EPS (TTM) | Rs | 55.5 | 53.3 | 54.5 | 53.8 | 44.6 | 44.0 | 45.0 | 44.0 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: AJANTA PHARMA 2QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: NOVARTIS IPCA LABS DR. REDDYS LAB PIRAMAL ENTERPRISES INDRAPRASTHA MEDICAL
Compare AJANTA PHARMA With: NOVARTIS IPCA LABS DR. REDDYS LAB PIRAMAL ENTERPRISES INDRAPRASTHA MEDICAL
Compare AJANTA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)
Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.
Views on news
AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)
Nov 8, 2019 | Updated on Nov 8, 2019For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)
Aug 2, 2019 | Updated on Aug 2, 2019For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Use My Secret to Increase Your Trading Profits Today
Dec 10, 2019What to do after every trade.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020 (Profit Hunter)
Dec 5, 2019This corner of the market could provide more returns than blue chips in 2020.
Make the Most of the Smallcap Rebound with These Stocks (Profit Hunter)
Dec 3, 2019Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
What Is the IPO Euphoria Signaling Us About the Markets? (The 5 Minute Wrapup)
Dec 2, 20192019 will be remembered as the year of great money-making IPOs...
More|
| |
AJANTA PHARMA SHARE PRICE
Dec 13, 2019 (Close)
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 5-YR ANALYSIS
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.